Literature DB >> 12818869

A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings.

Bruno Damascelli1, Gian Luigi Patelli, Rodolfo Lanocita, Giuseppe Di Tolla, Laura Francesca Frigerio, Alfonso Marchianò, Francesco Garbagnati, Carlo Spreafico, Vladimira Tichà, Caroline Regna Gladin, Mauro Palazzi, Flavio Crippa, Cesare Oldini, Stefano Calò, Alberto Bonaccorsi, Franco Mattavelli, Luigi Costa, Luigi Mariani, Giulio Cantù.   

Abstract

OBJECTIVE: The purpose of our study was to evaluate the effectiveness of intraarterial infusion of paclitaxel incorporated into human albumin nanoparticles for use as induction chemotherapy before definitive treatment of advanced squamous cell carcinoma of the tongue. SUBJECTS AND METHODS: Twenty-three previously untreated patients (age range, 27-75 years) who had carcinoma of the tongue (stage T3-T4, any N) received intraarterial therapy with paclitaxel incorporated into albumin nanoparticles delivered by transfemoral catheterization into the external carotid artery (10 patients), selectively into the lingual artery (12 patients), or into a faciolingual trunk (1 patient). Each patient received two to four infusions, with a 3-week interval between infusions. The dose administered was 230 mg/m(2) in eight patients, 180 mg/m(2) in six patients, and 150 mg/m(2) in nine patients. Sixteen patients underwent surgery. Of these 16 patients, eight subsequently received radiotherapy, and three received a combination of chemotherapy and radiotherapy. Of the remaining seven patients, one received chemotherapy alone, four received radiotherapy alone, one received chemotherapy plus radiotherapy, and one refused any further treatment.
RESULTS: Sixty-seven infusions were performed successfully. Eighteen patients (78%) had a clinical and radiologic objective response (complete, 26%; partial, 52%). Three patients (13%) showed stable disease, and two (9%) showed disease progression. The four patients with complete clinical response who underwent surgery showed microscopic residual carcinoma measuring less than 1 mm in two patients, less than 5 mm in one patient, and less than 1 cm in one patient. The toxicities encountered were hematologic (grade 3) in two patients (8.6%) and neurologic (grade 4) in two patients (reversible paralysis of the facial nerve, 8.6%). Two catheter-related complications occurred: one reversible brachiofacial paralysis and one asymptomatic occlusion of the external carotid artery.
CONCLUSION: Intraarterial infusion of paclitaxel in albumin nanoparticles proved reproducible and effective and deserves further investigation as induction chemotherapy before definitive treatment of advanced tumors of the tongue, with a view to organ preservation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818869     DOI: 10.2214/ajr.181.1.1810253

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  14 in total

1.  Study of thyro-lingual trunk and its clinical relevance.

Authors:  Madan Kapre; Ashutosh S Mangalgiri; Devendra Mahore
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-12-20

2.  HSA-curcumin nanoparticles: a promising substitution for Curcumin as a Cancer chemoprevention and therapy.

Authors:  Zahra Matloubi; Zuhair Hassan
Journal:  Daru       Date:  2020-04-08       Impact factor: 3.117

3.  Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids.

Authors:  Junping Wang; Dimitry Mongayt; Vladimir P Torchilin
Journal:  J Drug Target       Date:  2005-01       Impact factor: 5.121

4.  Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.

Authors:  Larisa Sheihet; Olga B Garbuzenko; Jared Bushman; Murugesan K Gounder; Tamara Minko; Joachim Kohn
Journal:  Eur J Pharm Sci       Date:  2011-12-03       Impact factor: 4.384

5.  Radiation-guided drug delivery to mouse models of lung cancer.

Authors:  Ghazal Hariri; Heping Yan; Hailun Wang; Zhaozhong Han; Dennis E Hallahan
Journal:  Clin Cancer Res       Date:  2010-08-27       Impact factor: 12.531

6.  Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement.

Authors:  Apostolia M Tsimberidou; Katherine Letourneau; Siqing Fu; David Hong; Aung Naing; Jennifer Wheler; Cynthia Uehara; Stephen E McRae; Sijin Wen; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-13       Impact factor: 3.333

7.  Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.

Authors:  Francesco Di Costanzo; Silvia Gasperoni; Virginia Rotella; Federica Di Costanzo
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

8.  SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients.

Authors:  Neil Desai; Vuong Trieu; Bruno Damascelli; Patrick Soon-Shiong
Journal:  Transl Oncol       Date:  2009-05       Impact factor: 4.243

Review 9.  Drug delivery and nanoparticles:applications and hazards.

Authors:  Wim H De Jong; Paul J A Borm
Journal:  Int J Nanomedicine       Date:  2008

10.  Intra-arterial chemoradiotherapy for locally advanced oral cavity cancer: analysis of therapeutic results in 134 cases.

Authors:  N Fuwa; T Kodaira; K Furutani; H Tachibana; T Nakamura; R Nakahara; T Tomoda; H Inokuchi; T Daimon
Journal:  Br J Cancer       Date:  2008-02-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.